news archive

BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

12.13.2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12.08.2023

BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

12.05.2023

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

11.12.2023

BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023

11.09.2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

11.08.2023

BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update

11.02.2023

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10.11.2023

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

10.10.2023

BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

10.09.2023

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments

10.03.2023

BridgeBio Pharma Announces $250 Million Private Placement Equity Financing

09.25.2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

09.08.2023

BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

09.07.2023

BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

09.06.2023

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023

08.27.2023

BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

08.24.2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08.04.2023

BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update

08.03.2023

BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study

07.31.2023

news archive

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BridgeBio disavows any obligation to update the information contained in such press releases after the date of their issuance.

back to news

icon icon